Promising results from early clinical experience with anti-CD19 CAR T cells in patients with autoimmune diseasesOptimal CAR construct design contributing to an acceptable safety profile, and potential for lasting immune reset are key for treatment adoption Kyverna is currently recruiting for multiple KYSA trials where the company's product candidate KYV-101 is used to treat patients suffering from myasthenia gravis, multiple sclerosis, and lupus nephritisEMERYVILLE, Calif., June 10, 2024 /PRNewswire/ -- Kyv ...

CAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4 ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced preliminary safety and efficacy results from its ...

 Novel and proprietary CAR-T approach holds potential to be first effective CAR-T therapy for solid tumorsSAN JOSE, Calif., May 21, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that treatment has commenced for the fifth patient in its ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer. The study is be ...

CT-0525 is the first CAR-Monocyte to be evaluated in humans in the solid tumor settingInitial data expected by year-end 2024PHILADELPHIA, May 16, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the first patient was dosed in its Phase 1 clinical trial evaluating CT-0525, an ex vivo gene-modified autologous chimeric antigen receptor-mono ...

PARSIPPANY, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ:CAR) (the "Company") announced today that its wholly-owned subsidiary, Avis Budget Finance plc (the "Issuer"), priced a private offering of €200 million aggregate principal amount of additional 7.25% Senior Notes due 2030 (the "Notes"). The Notes will be issued as additional notes under the Indenture, dated as of July 13, 2023, pursuant to which the Issuer previously issued €400 million aggregate principal amount of 7.25% Sen ...

PARSIPPANY, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ:CAR) (the "Company") announced today that its wholly-owned subsidiary, Avis Budget Finance plc (the "Issuer"), intends, subject to market and other customary conditions, to offer €200 million aggregate principal amount of additional 7.25% Senior Notes due 2030 (the "Notes") in a private offering. The Notes will be issued as additional notes under the Indenture, dated as of July 13, 2023, pursuant to which the Issuer previousl ...

Avis Budget Group, Inc. (CAR) reported mixed first-quarter 2024 results, wherein earnings missed the Zacks Consensus Estimate but revenues beat the same.The stock has gained 28.3% since its earnings release on May 1 despite the earnings miss.CAR’s adjusted loss was $3.2 per share compared with the Zacks Consensus Estimate of a loss of $3.15 and year-ago earnings of $7.72. Total revenues of $2.6 billion beat the consensus estimate by a slight margin but decreased marginally year over year.Avis Budget’s share ...

Avis Budget Group, Inc. (NASDAQ:CAR) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants David Calabria - Senior Vice President, Corporate Finance and Treasurer Joe Ferraro - President and Chief Executive Officer Izzy Martins - Executive Vice President and Chief Financial Officer Conference Call Participants Ryan Brinkman - J.P. Morgan John Babcock - Bank of America Chris Stathoulopoulos - Susquehanna Chris Woronka - Deutsche Bank Harold Antor - Jefferies John Healy - Northcoast Res ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File No. 001-10308 Avis Budget Group, Inc. (Exact name of registrant as specified in its charter) Delaware 06-0918165 (State ...

For the quarter ended March 2024, Avis Budget Group (CAR) reported revenue of $2.55 billion, down 0.2% over the same period last year. EPS came in at -$3.21, compared to $7.72 in the year-ago quarter.The reported revenue represents a surprise of +0.75% over the Zacks Consensus Estimate of $2.53 billion. With the consensus EPS estimate being -$3.15, the EPS surprise was -1.90%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determin ...